Search

Displaying results 3741 - 3750 of 4238 in total
  1. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of ...

  2. Drug

    Cyclizine

    go.drugbank.com/drugs/DB01176
    ApprovedWithdrawn

    A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)

  3. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    Aficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...

  4. Drug

    CIGB-258 peptide

    go.drugbank.com/drugs/DB15809
    Experimental

    As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens

  5. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.

  6. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    AZD-2836 is an inhibitor of the nonstructural protein 5A (NS5A). The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.

  7. Drug

    Allogeneic Cardiosphere-Derived Cells

    go.drugbank.com/drugs/DB15744
    Investigational

    Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used ...

  8. Drug

    SGX-523

    go.drugbank.com/drugs/DB06314
    Investigational

    A MET receptor tyrosine kinase inhibitor.

  9. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis.

  10. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in